Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will
evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system
suppressing medications with or without infusions of bone marrow stem cells from the kidney
donor. The purpose of this study is to find out which strategy is more effective in
preventing organ rejection and maintaining patient health.